Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSHPG1860 is a farnesoid X receptor (FXR) agonist.1 It induces luminescence in a reporter assay using HEK293T cells expressing human FXR (EC50 = 18 nM). In vivo, HPG1860 (1, 3, or 10 mg/kg per day) decreases the serum levels of alanine transaminase (ALT) and total cholesterol, as well as hepatic inflammation, fat levels, and fibrosis, in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a high-fat diet and carbon tetrachloride (CCl4).
WARNING This product is not for human or veterinary use.
1. Discovery of HPG1860, a structurally novel nonbile acid FXR agonist currently in clinical development for the treatment of nonalcoholic steatohepatitis. J. Med. Chem. 66(14), 9363-9375 (2023).